Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.65 |
| ▸ | MME | P08473 | 1/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | CPA2 | P48052 | 1/20 | 0.49 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7267746 | 1.00 | ACE (0.65) | ACEMMEMMP2MMP9ERAP2 | |
| SCHEMBL5870137 | 1.00 | ACE (0.65) | ACEMMEMMP2MMP9ERAP2 | |
| SCHEMBL6237696 | 0.90 | ACE (0.58) | ACEMMEMMP2MMP9ERAP2 | |
| SCHEMBL27458051 | 0.90 | ACE (0.58) | ACEMMEMMP2MMP9ERAP2 | |
| SCHEMBL6240311 | 0.90 | ACE (0.58) | ACEMMEMMP2MMP9ERAP2 | |
| SCHEMBL8255649 | 0.87 | MME (0.68) | ACEMME | |
| SCHEMBL29687687 | 0.87 | ACE (0.70) | ACEMMEERAP2ERAP1LNPEP | |
| SCHEMBL1133733 | 0.86 | ACE (0.53) | ACEMMEMMP2MMP9ERAP2 | |
| SCHEMBL6064398 | 0.86 | ACE (0.70) | ACEMMEMMP2MMP9ERAP2 | |
| SCHEMBL11113260 | 0.86 | ACE (0.53) | ACEMMEMMP2MMP9ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121667277-A | CBP lysine children growth milk powder and preparation method thereof | 大庆市绿叶乳品有限公司 | 2026-03-17 | — | — | CN | disclosed |
| US-11771733-B2 | Lisinopril formulations | Silvergate Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220111000-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2022-04-14 | — | — | US | disclosed |
| US-11179434-B2 | Lisinopril formulations | Silvergate Pharmaceuticals Inc. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210187055-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2021-06-24 | — | — | US | disclosed |
| US-10940177-B2 | Lisinopril formulations | Silvergate Pharmaceuticals, Inc. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200237851-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2020-07-30 | — | — | US | disclosed |
| US-20200206298-A1 | LISINOPRIL FORMULATIONS | AZURITY PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| US-10406199-B2 | Lisinopril formulations | Silvergate Pharmaceuticals, Inc. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190201475-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2019-07-04 | — | — | US | disclosed |
| US-10039800-B2 | Lisinopril formulations | Silvergate Pharmaceuticals, Inc. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180078604-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2018-03-22 | — | — | US | disclosed |
| US-9814751-B2 | Lisinopril formulations | Silvergate Pharmaceuticals, Inc. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170209523-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2017-07-27 | — | — | US | disclosed |
| US-20170119840-A1 | LISINOPRIL FORMULATIONS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2017-05-04 | — | — | US | disclosed |
| US-9616096-B1 | Lisinopril formulations | Silvergate Pharmaceuticals, Inc. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9463183-B1 | Lisinopril formulations | Silvergate Pharmaceuticals, Inc. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20120045505-A1 | FIXED DOSE DRUG COMBINATION FORMULATIONS | DR. REDDY'S LABORATORIES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| EP-0239062-B1 | N2-(1-CARBOXY-3-OXO-3-PHENYLPROPYL)-L-LYSINE COMPOUNDS AND THEIR DERIVATIVES | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-05-29 | — | — | EP | disclosed |
| EP-0239062-A2 | N2-(1-carboxy-3-oxo-3-phenylpropyl)-L-Lysine compounds and their derivatives | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187055-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-20220111000-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-20120045505-A1 | FIXED DOSE DRUG COMBINATION FORMULATIONS | SLC5A6, TNNT2, SIRT6 | ACE 14/4885MME 967/4885MMP2 4690/4885 |
| US-20170209523-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-10406199-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-20200206298-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-11179434-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-10940177-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-10039800-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-11771733-B2 | Lisinopril formulations | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-20190201475-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-20170119840-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-20200237851-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
| US-20180078604-A1 | LISINOPRIL FORMULATIONS | REN, ACE, AGT | ACE 2/4885MME 287/4885MMP2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.